Walvax announces the receipt of the purchase order from Morocco for the 13-valent pneumococcal polysaccharide conjugate vaccine
May 13, 2022, Kunming — Walvax Biotechnology Co., Ltd.’s ("Company") holding subsidiary Yuxi Walvax Biotechnology Co., Ltd. ("Yuxi Walvax") recently received the purchase order of the first batch of one million doses of its 13-valent pneumococcal polysaccharide conjugate vaccine ("PCV13") issued by the Ministry of Health of Morocco. Yuxi Walvax will start supplying its PCV13 products to Morocco according to the delivery schedule stipulated in the purchase order.
ㅤ
In April 2021, Yuxi Walvax and a Moroccan company entered into an exclusive distribution agreement on PCV13 for the Territory of Morocco, having reached a cooperation on the import, distribution and sales of finished products, as well as technology transfer and bulk supply for localization. (For details, please refer to the "Announcement on Signing an Overseas Distribution Agreement of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine" disclosed by the Company on http://www.cninfo.com.cn on April 28, 2021, Announcement No.: 2021-041). This purchase order is the first order placed under the Agreement.
ㅤ
Obtaining the purchase order of the PCV13 from Morocco is in line with the Company's internationalization strategy, and it is of great significance for this product to tap into the international market. The sales of PCV13 in Morocco are expected to have a positive impact on the Company's operating results.
ㅤ
ㅤ
Read the original announcement.